Latest Breaking News On - Janssen research development - Page 1 : comparemela.com

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis

The Company1 enters agreement with Numab Therapeutics to acquire its wholly owned subsidiary2 for the global rights to NM26, a Phase 2-ready investigational, first-in-class bispecific antibody.

Atropos Health Raises $33M to Scale the Automation of High-Quality, Personalized Real-World Evidence Leveraging Generative AI

Atropos Health lands $33M to close the evidence gap in medicine

The startup is focused on building out strategic partnerships with pharmaceutical companies and vertically integrated healthcare companies.